Giovanni Luca Ceresoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Giovanni Luca Ceresoli has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
5 shared publications - Arturo Chiti
Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
3 shared publications P. Zucali
3 shared publicationsA. Bearz
Department of Medical Oncology, National Cancer Institute, Centro di Riferimento Oncologico Aviano/IT
2 shared publicationsA. Santoro
2 shared publications- Adolfo Favaretto
Azienda ULSS 2 Marca Trevigiana, Treviso, Italy
2 shared publications
Latest Publications
- 1 November 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (11) , S1566-S1567
PS02.07 Telemedicine: A New Era for the Treatment of Patients with Cancer
- 1 November 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (11) , S1566-S1567
PS02.07 Telemedicine: A New Era for the Treatment of Patients with Cancer
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv33
Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)
Background: Following the results deriving from the RCT of VFL, this study aims to assess the generalizability of data in terms of overall survival in pts with metastatic TCCU in a large unselected population treated according to routine clinical practice.
- 21 September 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, iv33
Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)
Background: Following the results deriving from the RCT of VFL, this study aims to assess the generalizability of data in terms of overall survival in pts with metastatic TCCU in a large unselected population treated according to routine clinical practice.
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26 (suppl_6) , vi87
ATREUS Trial: A Phase II Study On The Activity Of Trabectedin In Pretreated Epithelioid Or Biphasic/Sarcomatoid Malignant Pleural Mesothelioma (MPM)
Background: Treatment options for patients (pts) with relapsing MPM are scarce. Moreover, the sarcomatoid and biphasic histotypes are generally resistant to treatment and outcome is poor. A viable regimen for 1st and 2nd line treatments is an unmet medical need. Trabectedin (T) is a natural marine compound that binds to the minor groove of DNA. It acts both directly on cancer cells and on tumor microenvironment, reducing the production of cytokines and chemokines and the number of tumor-associated macrophages. These features suggest a therapeutic potential for inflammation-related tumors, such as MPM. This study evaluates the activity and safety of T in pts with MPM.
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26 (suppl_6) , vi87
ATREUS Trial: A Phase II Study On The Activity Of Trabectedin In Pretreated Epithelioid Or Biphasic/Sarcomatoid Malignant Pleural Mesothelioma (MPM)
Background: Treatment options for patients (pts) with relapsing MPM are scarce. Moreover, the sarcomatoid and biphasic histotypes are generally resistant to treatment and outcome is poor. A viable regimen for 1st and 2nd line treatments is an unmet medical need. Trabectedin (T) is a natural marine compound that binds to the minor groove of DNA. It acts both directly on cancer cells and on tumor microenvironment, reducing the production of cytokines and chemokines and the number of tumor-associated macrophages. These features suggest a therapeutic potential for inflammation-related tumors, such as MPM. This study evaluates the activity and safety of T in pts with MPM.
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vi75
Activity and Safety of Trabectedin in patients with Sarcomatoid / Biphasic Malignant Pleural Mesothelioma (MPM)
- 26 September 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vi75
Activity and Safety of Trabectedin in patients with Sarcomatoid / Biphasic Malignant Pleural Mesothelioma (MPM)
- Open Access
- 10 June 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (1) , 51-56
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m−2 and carboplatin AUC 5 mg ml−1 min−1 intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those 70 years old. A total of 178 patients with an ECOG performance status of 2 were included. Median age was 65 years (range 38–79), with 48 patients 70 years (27%). Grade 3–4 haematological toxicity was slightly worse in 70 vs vs 13.8% (P=0.11), anaemia in 20.8 vs 6.9% (P=0.01) and thrombocytopenia in 14.6 vs 8.5% (P=0.26). Non-haematological toxicity was mild and similar in the two groups. No significant difference was observed in terms of overall disease control (60.4 vs 66.9%, P=0.47), time to progression (7.2 vs 7.5 months, P=0.42) and survival (10.7 vs 13.9 months, P=0.12). Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
- 10 June 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (1) , 51-56
Open AccessPemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m−2 and carboplatin AUC 5 mg ml−1 min−1 intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those 70 years old. A total of 178 patients with an ECOG performance status of 2 were included. Median age was 65 years (range 38–79), with 48 patients 70 years (27%). Grade 3–4 haematological toxicity was slightly worse in 70 vs vs 13.8% (P=0.11), anaemia in 20.8 vs 6.9% (P=0.01) and thrombocytopenia in 14.6 vs 8.5% (P=0.26). Non-haematological toxicity was mild and similar in the two groups. No significant difference was observed in terms of overall disease control (60.4 vs 66.9%, P=0.47), time to progression (7.2 vs 7.5 months, P=0.42) and survival (10.7 vs 13.9 months, P=0.12). Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 8099
NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
8099 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13 highly expressed on tumour blood vessels. NGR-hTNF combines direct anticancer activity and effects on tumour vascular permeability. In preclinical models, NGR-hTNF showed antitumor activity either at low doses or at high doses. Methods: Patients (pts) with advanced MPM pretreated with first-line chemotherapy received a low-dose of NGR-hTNF given at 0.8 mcg/m2 as 1-hour intravenous infusion every 3 weeks (q3w). This dose was previously selected in phase I trial based on dynamic imaging changes and preliminary clinical activity. The trial had a 2-stage design with 16 and 27 pts to be enrolled in first and second stage, respectively. Progression-free survival (PFS) was the primary end-point with reassessment performed q6w. Results: From May to December 2007, 42 pts were enrolled and 16 were included into the first-stage analysis: 75% were males; median age 64 years (range, 48–80); PS 0/1/2 7/6/3; 69% had epithelial, 12.5% sarcomatoid, 6% mixed and 12.5% unknown histology. Overall, 58 cycles (median 2, range: 1–9) were completed. Seven pts (44%; 95% CI 20- 68%) had a stable disease (SD) with a median duration of 4.4 months (range, 1.6–7.1+). The maximum changes of target lesions in SD pts ranged from 17% shrinkage to 6% growth. The estimated PFS rate at 4.5 months was 37% (95% CI 10–65%) and 3 pts (19%) are still on treatment at 6 months. To date, 26 pts are enrolled in stage 2 (5 SD, 3 PD, 18 too early) and an additional 12 pts are entering into a subsequent cohort of pts treated with a weekly schedule. Main grade 1–2 toxicities per patient were infusion-related constitutional symptoms, including chills (56%) and fatigue (31%). Neither grade 3–4 treatment-related adverse events nor toxicity-related death were observed. Conclusions: NGR-hTNF shows a favourable and manageable toxicity profile, with preliminary evidence of long-lasting disease control in chemo-pretreated MPM patients.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 8099
NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
8099 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13 highly expressed on tumour blood vessels. NGR-hTNF combines direct anticancer activity and effects on tumour vascular permeability. In preclinical models, NGR-hTNF showed antitumor activity either at low doses or at high doses. Methods: Patients (pts) with advanced MPM pretreated with first-line chemotherapy received a low-dose of NGR-hTNF given at 0.8 mcg/m2 as 1-hour intravenous infusion every 3 weeks (q3w). This dose was previously selected in phase I trial based on dynamic imaging changes and preliminary clinical activity. The trial had a 2-stage design with 16 and 27 pts to be enrolled in first and second stage, respectively. Progression-free survival (PFS) was the primary end-point with reassessment performed q6w. Results: From May to December 2007, 42 pts were enrolled and 16 were included into the first-stage analysis: 75% were males; median age 64 years (range, 48–80); PS 0/1/2 7/6/3; 69% had epithelial, 12.5% sarcomatoid, 6% mixed and 12.5% unknown histology. Overall, 58 cycles (median 2, range: 1–9) were completed. Seven pts (44%; 95% CI 20- 68%) had a stable disease (SD) with a median duration of 4.4 months (range, 1.6–7.1+). The maximum changes of target lesions in SD pts ranged from 17% shrinkage to 6% growth. The estimated PFS rate at 4.5 months was 37% (95% CI 10–65%) and 3 pts (19%) are still on treatment at 6 months. To date, 26 pts are enrolled in stage 2 (5 SD, 3 PD, 18 too early) and an additional 12 pts are entering into a subsequent cohort of pts treated with a weekly schedule. Main grade 1–2 toxicities per patient were infusion-related constitutional symptoms, including chills (56%) and fatigue (31%). Neither grade 3–4 treatment-related adverse events nor toxicity-related death were observed. Conclusions: NGR-hTNF shows a favourable and manageable toxicity profile, with preliminary evidence of long-lasting disease control in chemo-pretreated MPM patients.
- 8 November 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (19) , 1982-1984
11C-Labeled Methionine and Evaluation of Malignant Pleural Mesothelioma
Assessing responses to treatment on the basis of computed tomographic (CT) measurements in patients with malignant pleural mesothelioma is challenging because of the pattern of growth of this disease.1 There is evidence that 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) can detect the response of a tumor to chemotherapy or chemoradiotherapy early in the course of treatment.2 A few pilot studies have explored the role of FDG-PET in patients with malignant pleural mesothelioma who were treated with chemotherapy, with promising results.3 Nevertheless, the usefulness of FDG is limited by its uptake in inflammatory cells such as macrophages and activated lymphocytes, which can cause false positive findings in patients treated with palliative talc pleurodesis. False negative results in early epithelial malignant pleural mesothelioma have been reported.4
- 8 November 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (19) , 1982-1984
11C-Labeled Methionine and Evaluation of Malignant Pleural Mesothelioma
Assessing responses to treatment on the basis of computed tomographic (CT) measurements in patients with malignant pleural mesothelioma is challenging because of the pattern of growth of this disease.1 There is evidence that 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) can detect the response of a tumor to chemotherapy or chemoradiotherapy early in the course of treatment.2 A few pilot studies have explored the role of FDG-PET in patients with malignant pleural mesothelioma who were treated with chemotherapy, with promising results.3 Nevertheless, the usefulness of FDG is limited by its uptake in inflammatory cells such as macrophages and activated lymphocytes, which can cause false positive findings in patients treated with palliative talc pleurodesis. False negative results in early epithelial malignant pleural mesothelioma have been reported.4
- 31 October 2007
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 33 (6) , 533-541
Assessment of tumor response in malignant pleural mesothelioma
- 31 October 2007
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 33 (6) , 533-541
Assessment of tumor response in malignant pleural mesothelioma
- 1 July 2007
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (7) , 850-863
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Learning Objectives: After completing this course, the reader will be able to: Select appropriate treatment strategies for patients with MPM.Discuss the clinical development of new agents and therapeutic strategies, and how they could be integrated into the current armamentarium.Summarize the current understandings and pitfalls in staging MPM patients. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
- 1 July 2007
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (7) , 850-863
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Learning Objectives: After completing this course, the reader will be able to: Select appropriate treatment strategies for patients with MPM.Discuss the clinical development of new agents and therapeutic strategies, and how they could be integrated into the current armamentarium.Summarize the current understandings and pitfalls in staging MPM patients. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
- 1 January 2007
- Published by SAGE Publications in Tumori Journal
- Vol. 93 (1) , 88-96
Role of Computed Tomographyand [18F] Fluorodeoxyglucose Positron Emission Tomography Image Fusion in Conformal Radiotherapy of Non-Small Cell Lung Cancer: A Comparison with Standard Techniques with and without Elective Nodal Irradiation
Aims and background: Mediastinal elective node irradiation (ENI) in patients with non-small cell lung cancer candidate to radical radiotherapy is controversial. In this study, the impact of co-registered [18F]fluorodeoxyglucose-positron emission tomography (PET) and standard computed tomography (CT) on definition of target volumes and toxicity parameters was evaluated, by comparison with standard CT-based simulation with and without ENI. Methods: CT-based gross tumor volume (GTVCT) was first contoured by a single observer without knowledge of PET results. Subsequently, the integrated GTV based on PET/CT coregistered images (GTVPET/CT) was defined. Each patient was planned according to three different treatment techniques: 1) radiotherapy with ENI using the CT data set alone (ENI plan); 2) radiotherapy without ENI using the CT data set alone (no ENI plan); 3) radiotherapy without ENI using PET/CT fusion data set (PET plan). Rival plans were compared for each patient with respect to dose to the normal tissues (spinal cord, healthy lungs, heart and esophagus). Results: The addition of PET-modified TNM staging in 10/21 enrolled patients (48%); 3/21 were shifted to palliative treatment due to detection of metastatic disease or large tumor not amenable to high-dose radiotherapy. In 7/18 (39%) patients treated with radical radiotherapy, a significant (≥25%) change in volume between GTVCT and GTVPET/CT was observed. For all the organs at risk, ENI plans had dose values significantly greater than no-ENI and PET plans. Comparing no ENI and PET plans, no statistically significant difference was observed, except for maximum point dose to the spinal cord Dmax, which was significantly lower in PET plans. Notably, even in patients in whom PET/CT planning resulted in an increased GTV, toxicity parameters were fairly acceptable, and always more favorable than with ENI plans. Conclusions: Our study suggests that [18F]-fluorodeoxyglucose-PET should be integrated in no-ENI techniques, as it improves target volume delineation without a major increase in predicted toxicity.
- 1 January 2007
- Published by SAGE Publications in Tumori Journal
- Vol. 93 (1) , 88-96
Role of Computed Tomographyand [18F] Fluorodeoxyglucose Positron Emission Tomography Image Fusion in Conformal Radiotherapy of Non-Small Cell Lung Cancer: A Comparison with Standard Techniques with and without Elective Nodal Irradiation
Aims and background: Mediastinal elective node irradiation (ENI) in patients with non-small cell lung cancer candidate to radical radiotherapy is controversial. In this study, the impact of co-registered [18F]fluorodeoxyglucose-positron emission tomography (PET) and standard computed tomography (CT) on definition of target volumes and toxicity parameters was evaluated, by comparison with standard CT-based simulation with and without ENI. Methods: CT-based gross tumor volume (GTVCT) was first contoured by a single observer without knowledge of PET results. Subsequently, the integrated GTV based on PET/CT coregistered images (GTVPET/CT) was defined. Each patient was planned according to three different treatment techniques: 1) radiotherapy with ENI using the CT data set alone (ENI plan); 2) radiotherapy without ENI using the CT data set alone (no ENI plan); 3) radiotherapy without ENI using PET/CT fusion data set (PET plan). Rival plans were compared for each patient with respect to dose to the normal tissues (spinal cord, healthy lungs, heart and esophagus). Results: The addition of PET-modified TNM staging in 10/21 enrolled patients (48%); 3/21 were shifted to palliative treatment due to detection of metastatic disease or large tumor not amenable to high-dose radiotherapy. In 7/18 (39%) patients treated with radical radiotherapy, a significant (≥25%) change in volume between GTVCT and GTVPET/CT was observed. For all the organs at risk, ENI plans had dose values significantly greater than no-ENI and PET plans. Comparing no ENI and PET plans, no statistically significant difference was observed, except for maximum point dose to the spinal cord Dmax, which was significantly lower in PET plans. Notably, even in patients in whom PET/CT planning resulted in an increased GTV, toxicity parameters were fairly acceptable, and always more favorable than with ENI plans. Conclusions: Our study suggests that [18F]-fluorodeoxyglucose-PET should be integrated in no-ENI techniques, as it improves target volume delineation without a major increase in predicted toxicity.